| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ... Journal of hepatology 73 (1), 202-209, 2020 | 3842 | 2020 |
| Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904, 2018 | 1850 | 2018 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1211 | 2019 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 975 | 2021 |
| Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis RS Taylor, RJ Taylor, S Bayliss, H Hagström, P Nasr, JM Schattenberg, ... Gastroenterology 158 (6), 1611-1625. e12, 2020 | 888 | 2020 |
| Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis S McPherson, T Hardy, JF Dufour, S Petta, M Romero-Gomez, M Allison, ... Official journal of the American College of Gastroenterology| ACG 112 (5 …, 2017 | 802 | 2017 |
| A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis SA Harrison, P Bedossa, CD Guy, JM Schattenberg, R Loomba, R Taub, ... New England Journal of Medicine 390 (6), 497-509, 2024 | 609 | 2024 |
| Advancing the global public health agenda for NAFLD: a consensus statement JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, ... Nature Reviews Gastroenterology & Hepatology 19 (1), 60-78, 2022 | 588 | 2022 |
| A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH SM Francque, P Bedossa, V Ratziu, QM Anstee, E Bugianesi, AJ Sanyal, ... New England Journal of Medicine 385 (17), 1547-1558, 2021 | 505 | 2021 |
| JNK1 but not JNK2 promotes the development of steatohepatitis in mice JM Schattenberg, R Singh, Y Wang, JH Lefkowitch, RM Rigoli, ... Hepatology 43 (1), 163-172, 2006 | 456 | 2006 |
| Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆ QM Anstee, R Darlay, S Cockell, M Meroni, O Govaere, D Tiniakos, ... Journal of hepatology 73 (3), 505-515, 2020 | 437 | 2020 |
| Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis FE Mózes, JA Lee, EA Selvaraj, ANA Jayaswal, M Trauner, J Boursier, ... Gut 71 (5), 1006-1019, 2022 | 415 | 2022 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 406 | 2020 |
| Non‐alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches D Schuppan, JM Schattenberg Journal of gastroenterology and hepatology 28, 68-76, 2013 | 360 | 2013 |
| Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis G Farrell, JM Schattenberg, I Leclercq, MM Yeh, R Goldin, N Teoh, ... Hepatology 69 (5), 2241-2257, 2019 | 324 | 2019 |
| Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis O Govaere, S Cockell, D Tiniakos, R Queen, R Younes, M Vacca, ... Science translational medicine 12 (572), eaba4448, 2020 | 320 | 2020 |
| Liver injury in COVID-19: The current evidence SA Alqahtani, JM Schattenberg United European gastroenterology journal 8 (5), 509-519, 2020 | 308 | 2020 |
| Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis EA Selvaraj, FE Mózes, ANA Jayaswal, MH Zafarmand, Y Vali, JA Lee, ... Journal of hepatology 75 (4), 770-785, 2021 | 288 | 2021 |
| GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis J Best, LP Bechmann, JP Sowa, S Sydor, A Dechêne, K Pflanz, S Bedreli, ... Clinical gastroenterology and hepatology 18 (3), 728-735. e4, 2020 | 263 | 2020 |
| Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling JM Schattenberg, Y Wang, R Singh, RM Rigoli, MJ Czaja Journal of Biological Chemistry 280 (11), 9887-9894, 2005 | 261 | 2005 |
Peter GalleProfessor für Medizin, Mainz UniversityVerified email at uni-Mainz.de
